Rejuvenate Biomed

About

Rejuvenate Biomed is a clinical-stage biotechnology company based in Diepenbeek, Belgium, founded in 2017 by Ann Beliën, PhD. The company focuses on AI-enabled drug discovery to develop combination therapeutics from approved drugs that target multiple pathways of age-related diseases, promoting healthy aging. With a team of around 20 experts, Rejuvenate Biomed has made significant progress, including securing over $21.9 million in funding and advancing to clinical-stage status within seven years. The company utilizes two proprietary platforms: CombinAge™, an AI-driven drug discovery engine, and CelegAge™, an in vivo validation system using *C. elegans* to test drug combinations. Its lead candidate, RJx-01, is an oral combination of galantamine and metformin aimed at treating sarcopenia. Currently in Phase 1b trials, RJx-01 has shown promising results in improving muscle strength and function. Rejuvenate Biomed is committed to creating safe, synergistic drugs that address the root causes of age-related conditions, with a vision for healthier aging through scientific innovation.